Miochole (Acetylcholine Chloride)

Acetylcholine chloride, the active ingredient in Miochole, is a cholinergic agonist presented as a sterile intraocular preparation for ophthalmic use. It is employed to lower intraocular pressure in patients with glaucoma or ocular hypertension.

GNH USA supplies Miochole as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to multiple regions. Customers benefit from reliable logistics, batch traceability, and responsive technical support throughout the procurement process.

Miochole acts on the ocular cholinergic pathway to produce miotic effects and facilitate aqueous outflow.

- Glaucoma: reduces intraocular pressure by inducing pupil constriction and enhancing trabecular outflow. - Ocular hypertension: lowers elevated eye pressure through the same miotic mechanism, helping prevent progression to glaucoma. - Angle‑closure glaucoma (early stage): assists in opening the anterior chamber angle by shrinking the pupil, improving fluid drainage.

Acetylcholine chloride may cause ocular and systemic adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Transient blurred vision: temporary difficulty focusing after instillation. - Eye irritation or burning sensation: mild discomfort at the application site. - Redness of the conjunctiva: mild hyperemia of the eye. - Headache: occasional mild headache following treatment.

Serious or Rare Side Effects: - Persistent miosis: prolonged pupil constriction that may impair vision in low light. - Acute angle‑closure glaucoma: rapid increase in intraocular pressure in susceptible eyes. - Systemic cholinergic effects: bradycardia, hypotension, or bronchospasm in rare cases. - Severe allergic reaction: swelling, rash, or anaphylaxis requiring immediate medical attention.

When using Miochole, several precautions should be observed to ensure safety and efficacy.

- Indication confirmation: verify diagnosis of glaucoma or ocular hypertension before use. - Intraocular pressure monitoring: assess pressure regularly to adjust therapy as needed. - Narrow‑angle risk: avoid in patients with narrow‑angle anatomy unless supervised by an ophthalmologist. - Cardiovascular caution: use cautiously in patients with bradycardia or asthma due to possible systemic cholinergic absorption. - Concomitant miotics: do not combine with other miotic agents without specialist guidance. - Storage: Store at ambient temperature: keep in original container, protect from light and moisture.

Miochole can interact with other medications, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Systemic cholinesterase inhibitors (e.g., physostigmine): may cause additive cholinergic toxicity. - Other ocular miotics (e.g., pilocarpine): can lead to excessive miosis and discomfort. - Anticholinergic drugs (e.g., atropine): may antagonize the intended ocular effect.

Moderate Interactions (Monitor Closely): - Topical non‑steroidal anti‑inflammatory drugs: may increase ocular irritation. - Systemic antihistamines: can reduce miotic response, requiring dose adjustment. - Beta‑blocker eye drops: combined pressure‑lowering effect may be additive, monitor intraocular pressure. - Ocular anesthetics: may enhance systemic absorption of acetylcholine chloride.